Why the study?
Cardiovascular toxicities from oncologic treatments are increasingly identified, and beyond heart failure and cardiomyopathy, all components of the cardiovascular system can be affected.
This review highlights the importance of recognizing and managing electrophysiologic complications of cancer therapies through a multidisciplinary cardio-oncology approach.
Raises arrhythmia monitoring awareness in cancer patients; leaves open optimal prevention strategies for prospective trials.
In recent years, dramatic advances in both cancer diagnosis and treatment have led to significantly increased survival rates. As such, cardiovascular toxicities due to oncologic treatments are more frequently identified. Although heart failure and cardiomyopathy have historically been the cardiotoxicities most associated with cancer therapeutics, it is now recognized that all components of the cardiovascular system can be affected. In this review, we discuss electrophysiologic complications of cancer treatments, including atrial and ventricular tachyarrhythmias as well as bradyarrhythmias, and recommend a multidisciplinary approach with both cardiologists and oncologists to provide safe and effective care to these patients.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: